Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PT217 |
Trade Name | |
Synonyms | PT-217|PT 217 |
Drug Descriptions |
PT217 is a bispecific antibody that targets DLL3 and CD47, potentially resulting in enhanced tumor cell phagocytosis and inhibition of tumor growth (Cancer Res (2022) 82 (12_Supplement): 2908). |
DrugClasses | CD47 Antibody 31 DLL3 Antibody 6 |
CAS Registry Number | NA |
NCIT ID | C199289 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
PT217 | PT217 | 0 | 1 |